pemetrexed dipotassium · Avyxa Holdings · NDA 210661
Axtle
Earliest generic entry, as listed · earliest of 2 marketed strengths
25 Jun 2045
Blocked by patent: US 12721811.
Listed patents · 1 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 12721811 | product | 25 Jun 2045 |
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 2
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 210661 · 001 · RLD | powder, intravenous | EQ 100MG BASE/VIAL | 25 Jun 2045 |
| 210661 · 002 · RLD | powder, intravenous | EQ 500MG BASE/VIAL | 25 Jun 2045 |